You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.


Assessing Potential Implications of New Data on CMV Treatment in Transplant Recipients

  • Authors: Camille Nelson Kotton, MD, FIDSA, FAST; Atul Humar, MD, MSc FRCPC, FAST
  • CME / CE Released: 12/13/2022
  • Valid for credit through: 12/12/2023, 11:59 PM EST
Start Activity

  • Credits Available

    Physicians - maximum of 0.50 AMA PRA Category 1 Credit(s)™

    Nurses - 0.50 ANCC Contact Hour(s) (0 contact hours are in the area of pharmacology)

    Pharmacists - 0.50 Knowledge-based ACPE (0.050 CEUs)

    You Are Eligible For

    • Letter of Completion

Target Audience and Goal Statement

Infectious disease, nephrology, and transplantation clinicians and pharmacists who provide care for transplant patients with cytomegalovirus (CMV) infection.

The management of cytomegalovirus (CMV) infection or disease in transplant patients has historically been challenging due to side effects with older antiviral therapies, including myelotoxicity and renal toxicity. Side effect and efficacy data for newer improved transplant antiviral therapies, including maribavir and letermovir, is emerging rapidly. The goal of this activity is to help you learn about the emerging data and how to apply it in clinical practice when managing your transplant patients.

Upon completion of this activity, participants should be better able to: 

  • Employ late-breaking data on the efficacy of available antiviral therapies when managing cytomegalovirus (CMV) in solid organ transplant (SOT) patients
  • Utilize new data on the safety and tolerability of available antiviral therapies for CMV management in the SOT setting


Disclosure of Financial Relationships
RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.

Faculty Affiliation and Disclosures

  • Camille Nelson Kotton, MD, FIDSA, FAST

    Clinical Director, Transplant and Immunocompromised Host Infectious Diseases
    Infectious Diseases Division
    Massachusetts General Hospital
    Harvard Medical School
    Boston, Massachusetts, United States


    Camille Nelson Kotton, MD, FIDSA, FAST, has the following relevant financial relationships:
    Consultant or advisor for: Biotest, Evrys, Exevir, Hookipa, Merck, Oxford Immunotec, Roche Diagnostics, Takeda

  • Atul Humar, MD, MSc, FRCPC, FAST

    Professor, Department of Medicine
    University of Toronto
    R. Fraser Elliott Chair, Transplantation
    University Health Network
    Director, University of Toronto Transplant Institute
    Toronto, Ontario, Canada


    Atul Humar, MD, FRCPC, FAST, has the following relevant financial relationships:
    Consultant or advisor for: Astellas Pharma, Inc., Roche, Takeda

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

Disclosure of Unlabeled Use 

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. 


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities. 

Accreditation Statements

Interprofessional Continuing Education

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • RMEI Medical Education, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Contact This Provider

    For Nurses

  • The maximum number of hours awarded for this Continuing Nursing Education activity is 0.50 contact hour(s).

    Contact This Provider

    For Pharmacists

  • RMEI Medical Education, LLC designates this continuing education activity for 0.50 contact hour(s) (0.050 CEUs) of the Accreditation Council for Pharmacy Education.

    (Universal Activity Number - JA4008290-0000-22-006-H01-P)

    Type of Activity: Knowledge

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of  75%  on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. In addition, you must complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.


Assessing Potential Implications of New Data on CMV Treatment in Transplant Recipients

Authors: Camille Nelson Kotton, MD, FIDSA, FAST; Atul Humar, MD, MSc FRCPC, FASTFaculty and Disclosures

CME / CE Released: 12/13/2022

Valid for credit through: 12/12/2023, 11:59 PM EST


Learning Feedback Questions

Before you begin, please take this brief survey.

  • Print